Does DATOPOTAMAB DERUXTECAN-DLNK Cause Disease progression? 49 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 49 reports of Disease progression have been filed in association with DATOPOTAMAB DERUXTECAN-DLNK. This represents 29.7% of all adverse event reports for DATOPOTAMAB DERUXTECAN-DLNK.
49
Reports of Disease progression with DATOPOTAMAB DERUXTECAN-DLNK
29.7%
of all DATOPOTAMAB DERUXTECAN-DLNK reports
25
Deaths
8
Hospitalizations
How Dangerous Is Disease progression From DATOPOTAMAB DERUXTECAN-DLNK?
Of the 49 reports, 25 (51.0%) resulted in death, 8 (16.3%) required hospitalization.
Is Disease progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for DATOPOTAMAB DERUXTECAN-DLNK. However, 49 reports have been filed with the FAERS database.
What Other Side Effects Does DATOPOTAMAB DERUXTECAN-DLNK Cause?
Off label use (31)
Stomatitis (27)
No adverse event (22)
Nausea (11)
Prescribed underdose (9)
Death (7)
Interstitial lung disease (7)
Dyspnoea (6)
Mucosal inflammation (5)
Product prescribing issue (5)
What Other Drugs Cause Disease progression?
RITUXIMAB (7,282)
CYCLOPHOSPHAMIDE (7,100)
DOXORUBICIN (6,165)
VINCRISTINE (5,252)
PREDNISONE (5,096)
BEVACIZUMAB (4,653)
DEXAMETHASONE (4,545)
CARBOPLATIN (4,538)
CAPECITABINE (3,808)
ETOPOSIDE (3,776)
Which DATOPOTAMAB DERUXTECAN-DLNK Alternatives Have Lower Disease progression Risk?
DATOPOTAMAB DERUXTECAN-DLNK vs DAUNORUBICIN
DATOPOTAMAB DERUXTECAN-DLNK vs DAXIBOTULINUMTOXIN A-LANM
DATOPOTAMAB DERUXTECAN-DLNK vs DAYTRANA
DATOPOTAMAB DERUXTECAN-DLNK vs DECITABINE
DATOPOTAMAB DERUXTECAN-DLNK vs DEFERASIROX